San Francisco, CA — VeriSIM Life, with its leading AI-driven biosimulation platform transforming drug development, is proud to announce that its Founder and CEO, Dr. Jo Varshney, has been honored with the 2025 International Women Entrepreneur Award in IT by Great Companies.
The award recognizes exceptional women entrepreneurs across the globe who have demonstrated visionary leadership, technological innovation, and business excellence in the Information Technology sector. Dr. Varshney was selected for her pioneering work at the intersection of AI and biotechnology, where she has spearheaded the development of BIOiSIM™, a first-in-class platform that uses predictive modeling to simulate drug behavior in humans—dramatically reducing the cost, time, and failure rates associated with traditional drug development.
“This recognition is a testament not just to the technology we’ve built, but to the bold, interdisciplinary team that drives VeriSIM Life forward every day,” said Dr. Varshney. “We’re on a mission to fundamentally change how drugs are developed, making the process more humane, efficient, and effective. I’m honored to be among such an inspiring cohort of women leaders in IT.”
Founded in 2017, VeriSIM Life has quickly gained recognition for its ability to bridge the gap between preclinical research and clinical outcomes. Under Dr. Varshney’s leadership, the company has formed strategic partnerships with global pharmaceutical firms and secured multiple grants and accolades for innovation in life sciences and artificial intelligence.
The International Women Entrepreneur Award in IT is conferred annually by Great Companies, a platform that celebrates high-impact businesses and founders across diverse industries worldwide.
About VeriSIM Life
VeriSIM Life is transforming drug development through its proprietary AI-powered platform, BIOiSIM®. This advanced computational engine simulates human and animal biology to better predict the clinical success of drug candidates in early development. By reducing unnecessary testing and streamlining decision-making, BIOiSIM® drastically improves capital efficiency and reduces time to market for new therapies. To learn more, visit www.verisimlife.com.
AtlasGEN Novel Drug Designer efficiently identifies new molecules based on favorable chemical properties and simultaneously evaluates them for clinical safety and effectiveness based on biology using VeriSIM Life’s groundbreaking Translational Index™ technology.
Iterative ranking of target engaging hits by their Translational Index values reduces the time and cost associated with other computational hit discovery approaches, while compressing the hit-to-lead refinement and optimization process by pre-validating hits for translatability. This unique integration dramatically reduces the number of compounds to evaluate in subsequent experimental research.
The ability to generate target engaging compound hits depends largely on the size of the molecular search library. The AtlasGEN search space is supported by more than 1 trillion compounds. Generative AI and deep learning techniques deliver unprecedented discovery capability.
AtlasGEN accurately predicts protein-lygand binding affinity by combining geometric conformer analysis with machine learning based on experimental data 72% more efficiently than molecular docking-based approaches.
.png)
